[{"orgOrder":0,"company":"Beijing Pearl Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Pearl Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Pearl Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Pearl Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Pearl Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Pearl Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Pearl Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Pearl Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Pearl Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Beijing Pearl Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Pearl Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beijing Pearl Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Pearl Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Pearl Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Pearl Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Pearl Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Center, China","sponsor":"Beijing Avistone Pharmaceuticals Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Center, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Cancer Center, China \/ Beijing Avistone Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Center, China \/ Beijing Avistone Biotechnology"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"LaunXP Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vebreltinib","moa":"||c-MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apollomics Inc \/ LaunXP Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ LaunXP Biomedical"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Canaccord Genuity","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Canaccord Genuity"},{"orgOrder":0,"company":"Predicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Predicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Predicine \/ Apollomics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Predicine \/ Apollomics Inc"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APL-101","moa":"||tyrosine kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Maxpro Capital Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Maxpro Capital Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Maxpro Capital Acquisition Corp."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Ping An Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Ping An Capital","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Ping An Capital"}]
Find Clinical Drug Pipeline Developments & Deals for Vebreltinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
